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Abstract
Background KLK4::KLKP1 fusion is a recently described pseudogene that is enriched in prostate cancer (PCa). This new
biomarker has not been characterized in the Middle Eastern population.
Objective To establish the incidence and prognostic value of KLK4::KLKP1 fusion in a cohort of Middle Eastern men with
PCa and explore the relationship of this marker to other relevant biomarkers (PTEN, ERG, SPINK1).
Design, setting, and participants We interrogated a cohort of 340 Middle Eastern men with localized PCa treated by radical
prostatectomy between 2005 and 2015. KLK4::KLKP1 fusion status was assessed by RNA Chromogenic in situ hybridization
(CISH) and correlated to pathological and clinical parameters.
Outcome measurements and statistical analysis RNA-CISH expression of KLK4::KLKP1 was correlated with prognostic
factors, ERG, PTEN, and SPINK1 expression, and biochemical recurrence (BCR) following prostatectomy.
Results and limitations 51.7% of patient samples showed positive KLK4::KLKP1 expression; more commonly in cores of
PCa (38%) versus non-cancer (20.6%) (p < 0.0001) and in lower Gleason Grade Group tumors (1–3) vs (4–5). KLK4::KLKP1
expression positively correlated with ERG positivity and inversely associated with PTEN loss. No significant association
was found with SPINK1 expression, seminal vesicle invasion, positive surgical margin, pathological stage, or patient age
(< 50 or ≥ 50). The association between PTEN loss and BCR increased when combined with KLK4::KLKP1 negativity (HR
2.31, CI 1.03–5.20, p = 0.042).
Conclusions KLK4::KLKP1 expression is more common in this cohort of Middle Eastern men than has been reported in North
American men. It is associated with ERG positivity and inversely correlated with PTEN loss. In isolation, KLK4::KLKP1
expression was not significantly associated with clinical outcome or pathological parameters. However, its expression is
associated with certain molecular subtypes (ERG-positive, PTEN-intact) and as we demonstrate may help further stratify
the risk of recurrence within these groups.
Keywords KLK4::KLKP1 · Middle eastern · Prostate cancer · Biomarker · Prognosis
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Introduction
Prostate cancer (PCa) remains one of the commonest cancers worldwide and, excluding skin cancers, is the most
common cancer diagnosed in North American (NA) men
(Siegel et al. 2021). In the Middle East, the incidence is
much lower and may be due to a variety of factors, including lifestyle, diet, obesity, androgen levels, socioeconomic
status, and genetics (Al-Abdin and Al-Beeshi 2018). PCa
is also known to be a heterogeneous disease, which makes
the characterization and clinical implementation of biomarkers imperative to help guide treatment. As such, evaluation of molecular profiles that reflect molecular subtypes
of PCa in different ethnicities is needed (Kaffenberger and
Barbieri 2016).
Alteration in ETS-related gene (ERG) and phosphatase
and tensin homolog (PTEN) are among the most common
genomic alterations in prostate cancer. Rearrangements
between the androgen-regulated gene ERG and fusion
partner TMPRSS2 are identified in approximately half of
PCa’s in North America (Tomlins et al. 2008; Taylor et al.
2010) and often co-exist with PTEN deletions (Taylor et al.
2010; Bismar et al. 2018). Although ERG rearrangements
have been associated with poor prognosis in some studies
(Kaffenberger and Barbieri 2016), others have noted an
association with better outcomes in the setting of androgen
deprivation therapy (Bismar et al. 2012). These seemingly
conflicting relationships between molecular subtype and
outcome likely reflect differences between specific patient
populations and cohorts being investigated, as well as clinical endpoints assessed (Tomlins et al. 2008; Abou-Ouf
et al. 2016). For example, ERG rearrangements were of
lower incidence in a mixed Jordanian-Arab cohort with
transurethral and peripheral tumor localization (33.2%)
(Aldaoud et al. 2017) as well as in a study of a broader
Middle Eastern (ME) cohort with tumors that manifested
clinically (42.7%) (Abdelsalam et al. 2020).
PTEN deletions, as assessed by a surrogate of reduced
immunohistochemistry (IHC) expression, have been associated with worse clinical outcomes in PCa (Bismar et al.
2018; Guedes et al. 2017). In some studies, this adverse
clinical outcome appears to be more notable among men
with ERG-negative tumors compared to those with ERGpositive tumors (Bismar et al. 2018; Ahearn et al. 2015).
Serine Protease Inhibitor, Kazal Type 1 (SPINK1),
a trypsin inhibitor, has been documented to be overexpressed in a subset of ERG-negative tumors (Tomlins
et al. 2008). In a study by Flavin et. al, SPINK1 expression by IHC was detected in about 11% of ERG-negative
samples and 4% of ERG-positive cases. They found no
association between SPINK1 expression by IHC and Gleason grade grouping, tumor stage, biochemical recurrence
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(BCR), or PCa-specific mortality (Flavin et al. 2014). This
contrasts with other studies documenting an association
between SPINK1 expression and BCR (Terry et al. 2015).
Recently, we have started investigating molecular differences between ME and North American (NA) cohorts, in
order to identify and characterize any molecular differences
that could play a significant role in explaining the difference
in incidence and PCa progression between these two groups
and ultimately provide prognostic or therapeutic data.
Previously, we reported that ERG, PTEN, and SPINK1
genomic alterations occur less frequently in Middle Eastern men and that the association between of ERG positivity and PTEN loss noted in North American men was not
observed in this population (Abdelsalam et al. 2020). As
such, ethnically relevant molecular classification schema,
and ultimately subsequent biomarker implementation, are
vitally needed—what is of clinical relevance to one ethnic
background may be of limited utility to another.
However, unlike other common cancers, such as has
been seen with lung or breast cancer, there has been limited
clinical implementation of molecular biomarkers. Although
PTEN loss has recently been proposed as a potentially useful biomarker by the International Society of Urological
Pathology (ISUP), systematic use of prognostic biomarkers
in prostate cancer is currently not recommended by urological societies (Lotan et al. 2020), and the search for effective
clinical biomarkers continues.
Recently a new fusion has been identified that is
enriched in PCa. This involves the fusion of the androgenregulated gene KLK4 (Kallikrein Related Peptidase 4)
and the adjacent pseudogene KLKP1 (Kallikrein Pseudogene 1). Both KLK4 and KLKP1 belong to the kallikrein
family of serine proteases, and their genes are located
adjacent to each other in a cluster of 15 genes on chromosome 19 (q13.33–q13.4), also containing the wellknown KLK3 (Prostate-Specific Antigen) (Clements et al.
2001). The resulting chimeric sequence fuses the first two
exons of KLK4 with the last two exons of KLKP1 and
retains an open reading frame, incorporating 54 amino
acids encoded by the KLKP1 pseudogene in the putative
chimeric protein (Kalyana-Sundaram et al. 2012). The initial study documented this fusion to be highly expressed
in 30–50% of prostate cancer tissues (Kalyana-Sundaram
et al. 2012). In contrast, the fusion, if present at all, was only
expressed in very low relative levels in benign prostate tissue controls (Kalyana-Sundaram et al. 2012). Interestingly,
this readthrough was recently described in the PCa cell line
LNCaP as a cis sense-antisense chimeric transcript (Lai et al.
2010). A group in Sweden has identified another androgenregulated transcript from the same region (KLK4T2), which
appears to be a splice variant of KLK4 with exons of KLKP1.
In their study, they observed decreasing expression of both
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KLK4 and KLK4T2 from benign prostate to primary tumor,
to bone metastases, respectively (Lundwall et al. 2021).
Utilizing cell culture and a chicken chorioallantoic membrane (CAM) assay, expression of the KLK4::KLKP1 fusion
transcript was shown to affect cell proliferation, cell
invasion, tumor formation, and lymphovascular spread
(Chakravarthi et al. 2019). KLK4::KLKP1 expression was
studied via RNA in situ hybridization in a cohort of radical prostatectomy specimens from a racially diverse cohort
that included 38% African Americans, which noted positivity in 32% of PCa samples vs. 17% in benign prostate
tissue; with no association between KLK expression and
Gleason Grade Groups or race (African American vs Caucasian) (Chakravarthi et al. 2019). However, there was an
increased expression in the younger age group (< 50) as
well as an association between KLK4::KLKP1 expression
with positive ERG expression (p < 0.001) and lack of PTEN
loss (p = 0.032) by IHC. No association was noticed with
SPINK1 expression by IHC or ETV1, ETV4, or ETV5 by
dual RNA-CISH (Chakravarthi et al. 2019).
Since the study was reported in 2019, there has yet to be
further characterization of this fusion in terms of its expression in other ethnicities. This is the first paper to our knowledge to further explore this recurrent gene fusion in PCa
within the ME population.

Methods
Tissue microarray construction
Study population and tissue microarray construction
The study cohort consisted of Middle Eastern men diagnosed with localized PCa (n = 340). The cohort samples
were collected between 2005 and 2015, with a median follow-up of 6 years. The study was approved by the University
of Calgary, Cumming School of Medicine Ethics Review
Board. The cohort's samples were assembled on five tissue
microarrays (TMAs) with an average of two to five cores
per patient, including PCa, and adjacent benign tissue when
available, using a manual tissue arrayer (Beecher Instruments, Silver Spring, MD, USA).
KLK4::KLKP1 RNA‑CISH and IHC
RNA Chromogen in situ hybridization (CISH) was performed as described previously using RNAscope2.5 HD
Reagent Kit (ACDBio, catalog #322,350) according to the
manufacturer's instructions. In brief, after baking, deparaffinization, and target retrieval per manufacturer's instructions, TMA slides were incubated with target probes for
KLK4::KLKP1 for 2 h at 40 °C in a humidity chamber. After

detection and color development, slides were washed twice
in deionized water and then counterstained in hematoxylin (AgilentDAKO, catalog #K800821-2) for 5 min. Slides
were washed several times in tap water, then dried, dipped in
xylene, and mounted in EcoMount (Fisher, catalog #50-82832). Next, the slides were scanned using a digital imaging
system (Aperio Scanner, Leica). The images were reviewed,
and the RNA-CISH signal on the TMAs was scored. Distinct punctate cytoplasmic dots were regarded as positive
KLK4::KLKP1(Fig. 1A–E) (Chakravarthi et al. 2019). Of
the original cohort (n = 340), 331 patients had analyzable
results for KLK4::KLKP1 expression.
PTEN and ERG protein expression were assessed using
an ERG-PTEN dual-color IHC staining protocol and
SPINK1 as single-color IHC as described by Huang et al.
(2016). Benign prostatic glands and stromal tissue acted as
internal positive controls (Bismar et al. 2018). PTEN IHC
expression was assessed using a four-tiered system (0, negative; 1, weak; 2, moderate; and 3, high expression). SPINK1
and ERG IHC were assessed as a two-tiered system (0, negative; 1, positive) (Fig. 1F–H).
Pathological analysis
Histological diagnoses of individual TMA cores were confirmed by one study pathologist (T.A.B.) on the initial slides.
Gleason score grouping was assessed according to the 2014
World Health Organization/ International Society of Urological Pathology Grade Groups (GGs). In each patient, the
two predominant patterns of PCa were sampled and included
on the TMAs for analysis.
2.4. Statistical analysis SPSS version 25 was used to conduct all statistical analyses (IBM SPSS Statistics for Windows, version 25.0, released 2017; IBM Corp., Armonk, NY,
USA). Frequency and proportions were reported for categorical data. The chi-square test was used to compare two
categorical variables and Fisher's exact test was used where
the cell frequencies were < 5. A p value of < 0.05 was used
for statistical significance, and two-sided tests were utilized.

Results
KLK4::KLKP1 RNA‑CISH expression in PCa in ME
men and relation to Gleason score grouping,
pathological parameters, and other known
biomarkers
Overall, KLK4::KLKP1 RNA-CISH positivity was noted
in 171/331 (51.7%) patients. KLK4::KLKP1 staining was
observed in both cancer and adjacent benign tissue but
was noted to be more common in PCa, seen in 38% of
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Fig. 1  KLK4::KLKP1 RNA-CISH expression: negative signal in
GG1 PCa (A 10x, B 20x). Positive signals in GG2 PCa (C 10x, D
20x). PTEN IHC (purple) and ERG IHC (brown) expression in GG1

PCa: PTEN pos, ERG pos (E), PTEN pos, ERG neg (F) (Notice the
endothelial cells acting as internal positive controls for ERG)

cancer samples versus 20.6% of non-cancer prostate samples (p < 0.0001) (Fig. 2).
Positive KLK4::KLKP1 RNA-CISH signal occurred
more frequently in patients with moderate/high PTEN
staining, compared to negative/weak PTEN staining
(49/77; 63.6% vs. 122/250; 48.8% of cases (p = 0.023)).
KLK4::KLKP1 RNA positivity was higher in patients
with ERG positivity (86/132; 65.2% of cases compared
to 83/189; 43.9% of ERG negative (p < 0.0001)). No

significant difference was noted between KLK4::KLKP1
expression and SPINK1 expression. In this cohort,
KLK4::KLKP1 positivity occurred in 73/134 (54.5%) of
SPINK1 negative patients vs 17/35 (48.6%) SPINK1 positive (p = 0.53).
Next, we analyzed KLK4::KLKP1 RNA-CISH expression in association with other biomarkers on a core-by-core
basis. In this cohort, any PTEN positivity (score 1, 2, or 3)
was associated with a higher incidence of KLK4::KLKP1
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Fig. 2  Incidence of KLK4::KLKP1 RNA-CISH expression in prostate
tissue of ME men. Non-cancer 20.6% and prostatic adenocarcinoma
38%

Table 1  KLK4::KLKP1 status
in association with other
biomarkers (PTEN, ERG and
SPINK1) based on core-by-core
status

RNA-CISH positivity (80.4% vs 74.7%), and ERG positivity
was associated with a higher incidence of KLK4::KLKP1
RNA-CISH positivity (34.5% vs 15.8%) (p = 0.035 and
p < 0.0001, respectively) (Table 1).
Investigating KLK4::KLKP1 RNA-CISH positivity in
association with other pathological parameters, there was
no association between KLK4::KLKP1 RNA-CISH signal
and Gleason Score (p = 0.581), seminal vesicle invasion
(p = 0.775), positive surgical margin (p = 0.112), or pathological stage (p = 0.812). Additionally, there was no association between KLK4::KLKP1 RNA-CISH positivity and
patient age < 50 vs ≥ 50 (p = 0.286) (Table 2).
I n s u m m a r y, i n t h i s c o h o r t o f M E m e n ,
KLK4::KLKP1 RNA-CISH expression was inversely
associated with PTEN loss and positively associated with
ERG expression. There was no association with SPINK1
expression.

Variables

KLK4::KLKP1 negative

KLK4::KLKP1 positive

PTEN Score 0
PTEN Score 1, 2 or 3
PTEN Score 0 or 1
PTEN Score 2 or 3
ERG Score 0
ERG Score 1
SPINK1 Score 0
SPINK1 Score 1

194 (25.3%)
574 (74.7%)
463 (60.3%)
305 (39.7%)
631 (84.2%)
118 (15.8%)
382 (91.4%)
36 (8.6%)

73 (19.6%)
299 (80.4%)
179 (48.1%)
193 (51.9%)
239 (65.5%)
126 (34.5%)
176 (92.1%)
15 (7.8%)

p value
0.035
< 0.0001
< 0.0001
0.407

PTEN; 0 negative, 1 weak, 2 moderate, 3 high intensity
ERG, SPINK1; 0 negative, 1 positive intensity

Table 2  KLK4::KLKP1 status
in association with pathological
and clinical parameters

Parameter

Score

KLK4::KLKP1 RNACISH negative n (%)

KLK4::KLKP1 RNACISH positive n (%)

p value

Seminal vesicle invasion

Absent
Present
Absent
Present
Stage 2
Stage 3
6
3+4
4+3
8
9
Age ≥ 50
Age < 50

140 (89.2%)
17 (10.8%)
91 (58.0%)
66 (42.0%)
114 (72.6%)
43 (27.4%)
56 (35.9%)
54 (34.6%)
27 (17.3%)
14 (9.0%)
5 (3.2%)
155 (98.7%)
2 (1.3%)

149 (88.2%)
20 (11.8%)
83 (49.4%)
85 (50.6%)
120 (71.4%)
48 (28.6%)
54 (32.0%)
54 (32.0%)
41 (24.3%)
12 (7.1%)
8 (4.7%)
163 (96.4%)
6 (3.6%)

0.775

Positive surgical margin
Pathological stage
Gleason Score

Age (individual data)

0.112
0.812
0.581

0.286
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KLK4::KLKP1 RNA‑ISH expression in relation to BCR
post radical prostatectomy
There was no signif icant association between
KLK4::KLKP1 RNA-CISH expression and biochemical
recurrence (BCR). Only PTEN loss was associated with a
higher risk for BCR post radical prostatectomy (HR 1.98, CI
1.19–3.30, p = 0.009). Combining two biomarkers, PTEN
loss/KLK4::KLKP1 negativity was the only combination
showing significant association with BCR (HR 2.18, CI
1.03–4.62, p = 0.043), which was higher than PTEN alone.
This prognostic association remained significant in multivariate analysis after adjusting for Gleason score, surgical
margins, and pathological stage (HR 2.31, CI 1.03–5.20,
p = 0.042) (Table 3).

Table 3  KLK4::KLKP1 and
biomarkers status in association
with BCR post-radical
prostatectomy

Variables

Discussion
There is a great need to characterize biomarkers that are
reflective of the different molecular subtypes of PCa.
Describing these biomarkers in relation to ethnic backgrounds will enable better implementation in specific
populations. In this study, we characterized the incidence
and significance of KLK4::KLKP1 expression, a newly
described gene fusion found in PCa, in a cohort of ME men,
and explored its relationship to known biomarkers including
PTEN, ERG, and SPINK1 as well as its prognostic parameters in a surgical cohort.
In contrast to Chakravarthi et al.’s study, which described
this novel gene fusion in a NA cohort, KLK4::KLKP1
expression was found at higher rates in both noncancer and

Odds ratio

KLK4::KLKP1 Negative
Positive
0.99
0.60–1.62
ERG (Negative-score 0)
Positive- score 1
0.93
0.55–1.55
SPINK1 (Positive-Score 1)
Negative-score 0
0.90
0.37–2.16
PTEN (Positive-score 1,2,3)
Loss-score 0
1.98
1.19–3.30
KLK4::KLKP1 and ERG combined (KLK4::KLKP1 Negative and ERG Negative)
KLK4::KLKP1 Positive and ERG Positive
0.93
0.48–1.80
KLK4::KLKP1 Negative and ERG Positive
0.91
0.40–2.08
KLK4::KLKP1 Positive and ERG Negative
0.97
0.50–1.88
PTEN and ERG combined (PTEN Positive and ERG Negative)
PTEN Negative and ERG Positive
1.73
0.89–3.38
PTEN Negative and ERG Negative
1.83
0.86–3.90
PTEN Positive and ERG Positive
0.84
0.42–1.67
PTEN and KLK4::KLKP1 combined (PTEN Positive and KLK4::KLKP1 Negative)
PTEN Negative and KLK4::KLKP1 Positive
2.01
0.94–4.28
PTEN Negative and KLK4::KLKP1 Negative
2.18
1.03–4.62
PTEN Positive and KLK4::KLKP1 Positive
1.16
0.59–2.28
KLK4::KLKP1 and ERG combined (KLK4::KLKP1 negative and ERG Negative)*
KLK4::KLKP1 Positive and ERG Positive
0.95
0.46–1.93
KLK4::KLKP1 Negative and ERG Positive
1.05
0.43–2.54
KLK4::KLKP1 Positive and ERG Negative
1.05
0.52–2.14
PTEN and ERG combined (PTEN Positive and ERG Negative)*
PTEN Negative and ERG Positive
1.63
0.80–3.34
PTEN Negative and ERG Negative
1.47
0.65–3.34
PTEN Positive and ERG Positive
0.95
0.46–1.97
PTEN and KLK4::KLKP1 combined (PTEN gain and KLK4::KLKP1 negative)*
PTEN Negative and KLK4::KLKP1 Positive
1.66
0.73–3.76
PTEN Negative and KLK4::KLKP1 Negative
2.31
1.03–5.20
PTEN Positive and KLK4::KLKP1 Positive
1.35
0.66–2.80
*Adjusted for Gleason score, pathology stage and surgical margin
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95% CI

p value
0.958
0.769
0.812
0.009
0.827
0.827
0.930
0.107
0.117
0.616
0.070
0.043
0.662
0.877
0.917
0.884
0.180
0.354
0.888
0.227
0.042
0.413
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PCa cases in this ME cohort (20.6% and 38% vs 17% and
33%), respectively (Chakravarthi et al. 2019). This adds further data that suggested variable KLK4::KLKP1 expression
in different ethnicities: 51.4% in this cohort of ME men compared to 28% in African Americans and 34% in Caucasian
men in their study (Chakravarthi et al. 2019). We did not
find an association between KLK4::KLKP1 positivity and
patient age or other pathological parameters, including seminal vesicle invasion, Gleason score, surgical margin status,
or pathological stage. These findings mirror those of the NA
cohort (Chakravarthi et al. 2019).
As in the NA cohort, KLK4::KLKP1 expression was more
common in ERG-positive cases and cases with increased
PTEN expression. Interestingly, although no association
between KLK4::KLKP1 expression and BCR was noted, when
combined with PTEN status, KLK4::KLKP1 negativity/PTEN
loss demonstrated the highest risk of BCR in univariate and
multivariate analysis as compared to PTEN loss alone. This is
in line with literature suggesting that PTEN loss is associated
with worse disease (Bismar et al. 2018; Guedes et al. 2017). It
also suggests that KLK4::KLKP1 positivity could potentially
be somewhat protective when combined with PTEN loss, as
is the case for ERG expression when assessed in combination
with PTEN expression.
This latest observation is of particular note since we previously observed that ME men seem to not share the enrichment for PTEN deletions seen in ERG-positive tumors seen
in North America (Abdelsalam et al. 2020). Our observation
that KLK4::KLKP1 positivity tended to occur more in those
with retained PTEN may suggest a unique aspect of molecular
biology or tumorigenesis in ME men, and warrants further
investigation.
In summary, herein we describe KLK4::KLKP1 expression patterns in a PCa in a Middle Eastern cohort and outline
several similarities, as well as some important differences
between the original NA study (Chakravarthi et al. 2019).
In this ME cohort, the expression of KLK4::KLKP1 was
noted at increased rates in both benign and malignant prostate samples but retained similar expression patterns in
relation to Gleason grade groups and other biomarkers as
compared to the NA population. Additionally, the incidence
of KLK4::KLKP1 expression in this ME cohort was higher
compared to what was reported in Caucasian and African
American populations (51.4% vs 34 and 28%, respectively).
Although KLK4::KLKP1 did not show any prognostic value,
it showed a somewhat protective effect when combined with
PTEN loss. Its clustering with certain molecular markers
suggests a unique molecular profile (i.e., ERG-positive,
PTEN-retained) that may be associated with different pathways in PCa. Additional studies are needed to investigate if
KLK4::KLKP1 could be a useful marker to further stratify
PCa patients.
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